Adjuvant Erlotinib in Lung Cancer Prolongs Disease-Free Survival
(MedPage Today) -- No recurrence 2 years after surgery in almost 90% of EGFR+ NSCLC patients
Source: MedPage Today Primary Care - Category: Primary Care Source Type: news
More News: Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Primary Care | Tarceva